Korea Investment CORP Makes New Investment in Danaher Corporation $DHR

Korea Investment CORP bought a new stake in shares of Danaher Corporation (NYSE:DHR) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 168,366 shares of the conglomerate’s stock, valued at approximately $121,230,000.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Danaher during the second quarter worth $10,492,520,000. State Street Corp grew its holdings in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the period. Capital International Investors increased its position in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 9.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after buying an additional 1,334,221 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR opened at $219.42 on Friday. The company has a market cap of $154.25 billion, a P/E ratio of 38.97, a P/E/G ratio of 2.69 and a beta of 0.78. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company’s 50-day moving average price is $195.80 and its 200-day moving average price is $192.61. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.77 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Argus cut their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. HSBC dropped their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Wells Fargo & Company decreased their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Finally, Guggenheim lowered their price objective on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.